Marc Tessier-Lavigne - 03 Jan 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Reporting relationship: Director
Issuer ticker: REGN
Reported as of: 03 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2023, 15:16:35 UTC
Prior SEC filing: 28 Nov 2022
Next SEC filing: 05 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/**Marc Trevor Tessier-Lavigne

Key filing fact

Marc Tessier-Lavigne filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 05 Jan 2023.

Key facts

This page summarizes Marc Tessier-Lavigne's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2023, 15:16.

Change

Previous filing in this sequence was filed on 28 Nov 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

REGN transaction

Common Stock

Award

Transaction value: $0
Shares: +165
Change %: +7.3%
Price: $0.000000
Shares after: 2,434
Date: 03 Jan 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

REGN transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value: $0
Shares: +1,929
Change %
Price: $0.000000
Shares after: 1,929
Date: 03 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,929
Exercise price: $725.89
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

Footnote F2

On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.